Psychosocial consequences of false positives in the Danish Lung Cancer CT Screening Trial: a nested matched cohort study

Jakob Fraes Rasmussen, Volkert Siersma, Jessica Malmqvist, John Brodersen, Jakob Fraes Rasmussen, Volkert Siersma, Jessica Malmqvist, John Brodersen

Abstract

Objectives: Lung cancer CT screening can reduce lung cancer mortality, but high false-positive rates may cause adverse psychosocial consequences. The aim was to analyse the psychosocial consequences of false-positive lung cancer CT screening using the lung cancer screening-specific questionnaire, Consequences of Screening in Lung Cancer (COS-LC).

Design and setting: This study was a matched cohort study, nested in the randomised Danish Lung Cancer Screening Trial (DLCST).

Participants: Our study included all 130 participants in the DLCST with positive CT results in screening rounds 2-5, who had completed the COS-LC questionnaire. Participants were split into a true-positive and a false-positive group and were then matched 1:2 with a control group (n=248) on sex, age (±3 years) and the time of screening for the positive CT groups or clinic visit for the control group. The true positives and false positives were also matched 1:2 with participants with negative CT screening results (n=252).

Primary outcomes: Primary outcomes were psychosocial consequences measured at five time points.

Results: False positives experienced significantly more negative psychosocial consequences in seven outcomes at 1 week and in three outcomes at 1 month compared with the control group and the true-negative group (mean ∆ score >0 and p<0.001). True positives experienced significantly more negative psychosocial consequences in one outcome at 1 week (mean ∆ score 2.86 (95% CI 1.01 to 4.70), p=0.0024) and in five outcomes at 1 month (mean ∆ score >0 and p<0.004) compared with the true-negative group and the control group. No long-term psychosocial consequences were identified either in false positives or true positives.

Conclusions: Receiving a false-positive result in lung cancer screening was associated with negative short-term psychosocial consequences. These findings contribute to the evidence on harms of screening and should be taken into account when considering implementation of lung cancer screening programmes.

Trial registration number: NCT00496977.

Keywords: computed tomography; preventive medicine; public health; thoracic medicine.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Distribution of screening results and final diagnoses in the DLCST, and response rates of the matched groups at five time points: baseline, 1 week, 1, 6 and 18 months. COS-LC, Consequences of Screening in Lung Cancer; DLCST, Danish Lung Cancer Screening Trial.
Figure 2
Figure 2
The mean score of the nine psychosocial outcomes of Consequences of Screening in Lung Cancer (COS-LC) part I for the diagnostic groups and the control group in the Danish Lung Cancer Screening Trial at five time points: baseline, 1 week, 1, 6 and 18 months. The means of COS-LC part I scales are compared between all groups at each time point and significant differences between the groups are described below each scale (see online supplementary appendix 1 for details of the adjusted analyses). After adjustment for multiple testing by the method of Benjamini-Hochberg, the level of statistical significance was assessed at 0.0043; 0=baseline; 1 w=1 week after screening; 1 m, 6 ms and 18 ms=1, 6 and 18 months after final diagnostic result; the higher the score the more negative psychosocial reaction.
Figure 3
Figure 3
The mean score of the six psychosocial outcomes of Consequences of Screening in Lung Cancer (COS-LC) part II for the diagnostic groups in the Danish Lung Cancer Screening Trial at three time points: 1, 6 and 18 months. The means of COS-LS Part II scales are compared between the three screened groups at each time point after the final diagnostic result and significant differences between the groups are described below each scale (see online supplementary appendix 1 for details of the adjusted analyses). After adjustment for multiple testing by the method of Benjamini-Hochberg, the level of statistical significance was assessed at 0.0043; 0=baseline; 1 w=1 week after screening; 1 m, 6 ms and 18 ms=1, 6 and 18 months after final diagnostic result; the higher the score the more psychosocial reaction.

References

    1. Ott JJ, Ullrich A, Mascarenhas M, et al. . Global cancer incidence and mortality caused by behavior and infection. J Public Health 2011;33:223–33. 10.1093/pubmed/fdq076
    1. Shlomi D, Ben-Avi R, Balmor GR, et al. . Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J 2014;44:217–38. 10.1183/09031936.00164513
    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409. 10.1056/NEJMoa1102873
    1. Humphrey LL, Deffebach M, Pappas M, et al. . Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services Task force recommendation. Ann Intern Med 2013;159:411–20. 10.7326/0003-4819-159-6-201309170-00690
    1. Pinsky PF, Church TR, Izmirlian G, et al. . The National lung screening trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119:3976–83. 10.1002/cncr.28326
    1. Manser R, Lethaby A, Irving LB, et al. . Screening for lung cancer. Cochrane Database Syst Rev 2013:CD001991. 10.1002/14651858.CD001991.pub3
    1. Winkler Wille MM, van Riel SJ, Saghir Z, et al. . Predictive accuracy of the PanCan lung cancer risk prediction model -external validation based on CT from the Danish lung cancer screening trial. Eur Radiol 2015;25:3093–9. 10.1007/s00330-015-3689-0
    1. Field JK, van Klaveren R, Pedersen JH, et al. . European randomized lung cancer screening trials: post NLST. J Surg Oncol 2013;108:280–6. 10.1002/jso.23383
    1. Croswell JM, Baker SG, Marcus PM, et al. . Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010;152:505–12. W176-80. 10.7326/0003-4819-152-8-201004200-00007
    1. Barton MB, Moore S, Polk S, et al. . Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits. J Gen Intern Med 2001;16:150–6. 10.1111/j.1525-1497.2001.00329.x
    1. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. Pol Arch Med Wewn 2010;120:89–94. 10.20452/pamw.895
    1. Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013;11:106–15. 10.1370/afm.1466
    1. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Decis Making 2008;28:917–25. 10.1177/0272989X08322013
    1. Goulart BHL, Bensink ME, Mummy DG, et al. . Lung cancer screening with low-dose computed tomography: costs, National expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012;10:267–75. 10.6004/jnccn.2012.0023
    1. Rasmussen JF, Siersma V, Pedersen JH, et al. . Healthcare costs in the Danish randomised controlled lung cancer CT-screening trial: a registry study. Lung Cancer 2014;83:347–55. 10.1016/j.lungcan.2013.12.005
    1. Jensen MD, Siersma V, Rasmussen JF, et al. . Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study. BMJ Open 2020;10:e031768. 10.1136/bmjopen-2019-031768
    1. Saghir Z, Dirksen A, Ashraf H, et al. . CT screening for lung cancer brings forward early disease. The randomised Danish lung cancer screening trial: status after five annual screening rounds with low-dose CT. Thorax 2012;67:296–301. 10.1136/thoraxjnl-2011-200736
    1. Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. Value Health 2010;13:601–12. 10.1111/j.1524-4733.2010.00697.x
    1. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, et al. . Long-term effects of lung cancer computed tomography screening on health-related quality of life: the Nelson trial. Eur Respir J 2011;38:154–61. 10.1183/09031936.00123410
    1. Gareen IF, Duan F, Greco EM, et al. . Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National lung screening trial. Cancer 2014;120:3401–9. 10.1002/cncr.28833
    1. Brain K, Lifford KJ, Carter B, et al. . Long-term psychosocial outcomes of low-dose CT screening: results of the UK lung cancer screening randomised controlled trial. Thorax 2016;71:996–1005. 10.1136/thoraxjnl-2016-208283
    1. McCaffery KJ, Barratt AL. Assessing psychosocial/quality of life outcomes in screening: how do we do it better? J Epidemiol Community Health 2004;58:968–70. 10.1136/jech.2004.025114
    1. Pedersen JH, Ashraf H, Dirksen A, et al. . The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol 2009;4:608–14. 10.1097/JTO.0b013e3181a0d98f
    1. Andersen EB. A goodness of fit test for the Rasch model. Psychometrika 1973;38:123–40. 10.1007/BF02291180
    1. Dufouil C, Brayne C, Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. Stat Med 2004;23:2215–26. 10.1002/sim.1821
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289–300. 10.1111/j.2517-6161.1995.tb02031.x
    1. Chapple A, Ziebland S, McPherson A. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. BMJ 2004;328:1470. 10.1136/bmj.38111.639734.7C
    1. Hestbech MS, Siersma V, Dirksen A, et al. . Participation bias in a randomised trial of screening for lung cancer. Lung Cancer 2011;73:325–31. 10.1016/j.lungcan.2010.12.018
    1. Grannis FW. Minimizing over-diagnosis in lung cancer screening. J Surg Oncol 2013;108:289–93. 10.1002/jso.23400
    1. Rasmussen JF, Siersma V, Pedersen JH, et al. . Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer 2015;87:65–72. 10.1016/j.lungcan.2014.11.003
    1. Saghir Z, Ashraf H, Dirksen A, et al. . Contamination during 4 years of annual CT screening in the Danish lung cancer screening trial (DLCST). Lung Cancer 2011;71:323–7. 10.1016/j.lungcan.2010.06.006
    1. Lindberg LG, Svendsen M, Dømgaard M, et al. . Better safe than sorry: a long-term perspective on experiences with a false-positive screening mammography in Denmark. Health Risk Soc 2013;15:699–716. 10.1080/13698575.2013.848845
    1. Kaerlev L, Iachina M, Pedersen JH, et al. . CT-Screening for lung cancer does not increase the use of anxiolytic or antidepressant medication. BMC Cancer 2012;12:188. 10.1186/1471-2407-12-188
    1. Salz T, Richman AR, Brewer NT. Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. Psychooncology 2010;19:1026–34. 10.1002/pon.1676
    1. Kinsinger LS, Anderson C, Kim J, et al. . Implementation of lung cancer screening in the Veterans health administration. JAMA Intern Med 2017;177:399–406. 10.1001/jamainternmed.2016.9022

Source: PubMed

3
订阅